Pacira BioSciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PCRX research report →
Range $25 – $36.5
Price Chart
About the company
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide.
- CEO
- Frank D. Lee
- IPO
- 2011
- Employees
- 827
- HQ
- Brisbane, CA, US
Get TickerSpark's AI analysis on PCRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.46B
- P/E
- 38.32
- Fwd P/E
- 12.43
- PEG
- 0.36
- P/S
- 1.96
- P/B
- 2.04
- EV/EBITDA
- 11.79
- Div Yield
- 0.00%
- Gross Margin
- 78.73%
- Op Margin
- 4.62%
- Net Margin
- 5.08%
- ROE
- 5.53%
- ROIC
- 3.16%
Latest fiscal year · YoY change
- Revenue
- $726.41M+3.6%
- Gross Profit
- $576.66M+8.7%
- Op Income
- $33.30M
- Net Income
- $7.03M+107.1%
- EPS
- $0.16+107.4%
- OCF Growth
- -19.7%
- FCF Growth
- -23.5%
- 52W High
- $36.67
- 52W Low
- $18.80
- 50D MA
- $31.82
- 200D MA
- $25.97
- Beta
- 0.25
- RSI (14)
- 83
- Avg Volume
- 1.32M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Pacira delivered modest Q2 revenue growth and strong cash generation while leaning into payer access gains, pipeline catalysts, and a sharper pharma-focused strategy.· August 4, 2026
- Q2 revenue was $192.4 million, up 6% year over year, with EXPAREL at $147.8 million, ZILRETTA at $32.6 million, and iovera at $6.8 million.
- Non-GAAP gross margin was 78% versus 82% last year, and adjusted EBITDA was about $48.7 million.
- Management said EXPAREL gained penetration/share despite softer elective soft-tissue procedures and macro pressure, especially in inpatient settings.
- UnitedHealthcare coverage expanded EXPAREL to well over 150 million covered lives with separate reimbursement outside the bundle, moving toward a 160 million covered-life goal.
- 2026 guidance was updated for the Zimmer transaction: total revenue $735 million to $760 million, SG&A $310 million to $330 million, and stock-based comp $54 million to $59 million.
Second quarter total revenue was $192.4 million, up 6% versus Q2 2025. EXPAREL net sales were $147.8 million, up 3% from $142.9 million, with about 4% volume growth partially offset by vial mix and GPO-related discounting. ZILRETTA sales were $32.6 million, up 4% from $31.3 million, and iovera sales were $6.8 million, up 21% from $5.6 million. Non-GAAP gross margin was 78% versus 82% last year; non-GAAP R&D was $27.1 million versus $24.7 million; non-GAAP SG&A was $81.3 million versus $77.2 million; GAAP net income was $4.7 million, or $0.12 per diluted share; adjusted EBITDA was about $48.7 million. Cash and investments were $251 million, before the $70 million upfront Zimmer payment. Full-year 2026 guidance now calls for total revenue of $735 million to $760 million, SG&A of $310 million to $330 million, stock-based compensation of $54 million to $59 million, EXPAREL net product sales of $600 million to $620 million, non-GAAP gross margin of 77% to 79%, non-GAAP R&D of $105 million to $115 million, and about $30 million of depreciation expense. Management said the revenue guide still assumes about $7 million from veterinary licensing and that Q4 margins should be slightly below the full-year range due to higher-cost inventory, shutdown-related costs, and other expenses.
Frank Lee framed the quarter as evidence that Pacira is executing its 5x30 strategy and becoming a more innovation-driven pharmaceutical company. He emphasized commercial momentum, expanding payer access, pipeline catalysts, and partnerships, especially the Zimmer Biomet deal and LG Chem filing in South Korea. His tone was constructive and confident, while acknowledging that elective procedures can remain sensitive to macro conditions.
Shawn Cross highlighted that revenue rose 6% year over year to $192.4 million, while gross margin came in at 78% versus 82% last year. He explained the margin and expense profile with specific figures: R&D increased to $27.1 million, SG&A to $81.3 million, and adjusted EBITDA was about $48.7 million. He also pointed to a strong balance sheet with $251 million in cash and investments, plus a $70 million upfront payment from Zimmer, and updated full-year guidance mainly to reflect the transaction.
Analysts focused on whether NOPAIN reimbursement support could be extended beyond 2027 and how Pacira plans to pursue renewal; management said it is working both with CMS through the annual rulemaking cycle and with Congress, expecting any extension to be attached to a larger bill rather than standalone legislation. Questions also centered on softer EXPAREL volume growth and whether macro weakness would force a guide cut; management said the company is focusing on outpatient and other macro-resilient procedures, and that commercial payer wins and health-economic data support the second-half outlook. Another question asked about potentially partnering EXPAREL in the U.S.; management said it is open-minded about partnerships if they are cost-effective and value-accretive, while keeping direct sales capabilities.
The positive case from this call is that Pacira is still gaining share in EXPAREL and expanding reimbursement coverage, with UnitedHealthcare and other payers pushing coverage to well over 150 million lives. Management also pointed to multiple near-term catalysts, including top-line data for PCRX-201, ZILRETTA shoulder OA, and iovera spasticity, plus the Zimmer transaction and future partnership opportunities.
The main risks discussed were macro pressure on elective soft-tissue procedures, especially in hospital inpatient settings, and the possibility that short-term volume growth remains uneven. Margin also stepped down to 78% from 82% last year, and management noted Q4 margins should be slightly below the full-year range because of higher-cost inventory and shutdown-related costs. The NOPAIN provision is also a policy risk because management is working to renew it toward the end of next year rather than relying on an immediate extension.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.7%
- Shares Outstanding
- 39.91M
- Float Shares
- 38.59M
of shares held by institutions
257 13F filers
Buy/sell ratio 0.01. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for PCRX, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Tom MalinowskiHouse · NJ07 | Buy | May 6, 21 | Filing → |
| Tom MalinowskiHouse · NJ07 | Buy | Apr 20, 21 | Filing → |
| Tom MalinowskiHouse · NJ07 | Buy | Sep 26, 19 | Filing → |
| Tom MalinowskiHouse · NJ07 | Buy | May 31, 19 | Filing → |
| Tom MalinowskiHouse · NJ07 | Buy | Nov 2, 20 | Filing → |
| Tom MalinowskiHouse · NJ07 | Buy | Jan 15, 21 | Filing → |
| Tom MalinowskiHouse · NJ07 | Buy | Aug 23, 19 | Filing → |
| Tom MalinowskiHouse · NJ07 | Buy | May 30, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 6.94M | ▲ 229.99K |
| Vanguard Group Inc | 4.81M | ▼ 384.61K |
| Doma Perpetual Capital Management LLC | 2.78M | 0 |
| Vanguard Portfolio Management LLC | 2.37M | ▼ 33.95K |
| Dimensional Fund Advisors LP | 2.27M | ▲ 168.37K |
| State Street Corp | 2.15M | ▲ 85.32K |
| D. E. Shaw & Co., Inc. | 1.95M | ▼ 32.39K |
| Renaissance Technologies LLC | 1.67M | ▼ 61.90K |
| Vanguard Capital Management LLC | 1.63M | ▼ 64.99K |
| Goldman Sachs Group Inc | 1.53M | ▼ 42.79K |
| Morgan Stanley | 1.28M | ▲ 137.21K |
| American Century Companies Inc | 1.21M | ▲ 195.44K |
Held by 340 ETFs
Biggest fund positions in PCRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Lee Frank D. | sell | 660,830.841 |
| Nov 17, 26 | Lee Frank D. | sell | 692,512 |
| Nov 17, 26 | Young Alethia | sell | 17,798 |
| Nov 17, 26 | Young Alethia | sell | 12,179 |
| Nov 17, 26 | Young Alethia | sell | 11,279 |
| Nov 17, 26 | Young Alethia | sell | 10,891 |
| Nov 17, 26 | Young Alethia | sell | 30,967 |
| Nov 17, 26 | Hirawat Samit | sell | 6,405 |
| Nov 17, 26 | Hirawat Samit | sell | 10,891 |
| Nov 17, 26 | Hirawat Samit | sell | 39,291 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PCRX coverage
Recent articles, reports, and earnings notes.
No research on PCRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PCRX report →Viatris Completes Acquisition of Pacira BioSciences
prnewswire.com · Nov 17
Ingram Micro Holding Set to Join S&P SmallCap 600
prnewswire.com · Nov 11
Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT?
fool.com · Nov 11
Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX
businesswire.com · Nov 5
Viatris Reports Third-Quarter 2026 Financial Results
prnewswire.com · Nov 5
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?
globenewswire.com · Nov 4
Are BWIN, LFCR, PCRX Obtaining Fair Deals for their Shareholders?
prnewswire.com · Nov 3
INVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger - RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?
prnewswire.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.